Prime Editing Creates Drug-Controllable T Cell Therapies

Engineered T cells resisted tacrolimus but remained sensitive to cyclosporin, providing a potential way to select or suppress them after administration

October 28, 2026
3 min

The Medicine Maker

At a Glance

Category	Detail
Condition	Subcutaneous panniculitis-like T cell lymphoma with hemophagocytic lymphohistiocytosis, associated with HAVCR2 mutations; the platform is intended for therapeutic T cells used in settings requiring continued immunosuppression.
Key Mechanisms	Prime editing corrected the pathogenic HAVCR2 variant and altered FKBP1A to confer tacrolimus resistance while retaining cyclosporin sensitivity.
Target Population	The proposed use is in patients requiring continued immunosuppression, including organ or stem cell transplant recipients and people with immune disorders. Initial patient-derived cell testing used T cells from three people with subcutaneous panniculitis-like T cell lymphoma with hemophagocytic lymphohistiocytosis.
Care Setting	Preclinical research using patient-derived T cells and humanized and tumor-bearing mouse models.

Key Highlights

Prime editing corrected the pathogenic HAVCR2 variant in 18.7% to 35.8% of patient-derived T cells; TIM-3 surface expression was restored in up to 44.4%.
In a humanized mouse model, tacrolimus selection increased corrected HAVCR2 sequences to an average of 76.8% of spleen reads after eight weeks, compared with 9.3% without selection.
Edited cells remained sensitive to cyclosporin, which acts through a different pathway.
Tacrolimus-exposed edited CD19-directed CAR T cells retained viability, proliferation, and tumor-killing activity; edited cells maintained tumor control in mice bearing CD19-positive tumors.
Additional edits targeting resistance to methotrexate and mycophenolate showed resistance that varied according to the specific edit.

Guideline-Based Recommendations

Diagnosis

Study population: T cells from three patients with subcutaneous panniculitis-like T cell lymphoma with hemophagocytic lymphohistiocytosis, associated with HAVCR2 mutations.

Management

In the preclinical study, tacrolimus was used to select for edited T cells, and cyclosporin was tested as an alternative means of suppressing them.

Monitoring & Follow-up

The study assessed HAVCR2 correction, TIM-3 surface expression, edited-cell representation, cell viability, proliferation, and tumor-killing activity.

Risks

The approach is preclinical and was evaluated in patient-derived cells and mouse models.
Resistance to methotrexate and mycophenolate varied according to the specific edit.

Patient & Prescribing Data

The proposed use is for people who require continued immunosuppression, such as organ or stem cell transplant recipients and people with immune disorders. Initial patient-derived cell testing involved three people with subcutaneous panniculitis-like T cell lymphoma with hemophagocytic lymphohistiocytosis; the source does not report clinical use.

The engineered T cells were designed to resist tacrolimus while remaining sensitive to cyclosporin. The source reports preclinical findings and provides no clinical prescribing instructions.

Clinical Best Practices

Distinguish the reported preclinical findings from established clinical treatment: the platform was evaluated in patient-derived cells and mouse models.
The study tested tacrolimus as a selective pressure for edited cells and cyclosporin as a means of suppressing the edited population.
The article reports that edited CAR T cells retained viability, proliferation, and tumor-killing activity during tacrolimus exposure.